Skip to Content

Teva Pharmaceutical Industries Ltd TEVA

Morningstar Rating
Unlock our analysis with Morningstar Investor

About Quantitative Ratings

Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings. Companies with quantitative ratings are not formally covered by a Morningstar analyst, but are statistically matched to analyst-rated companies, allowing our models to calculate a quantitative moat, fair value, and uncertainty rating.

Price vs Fair Value

TEVA is trading at a 619% premium.
Price
ILS 63.58
Fair Value
ILS 12.86
Uncertainty
Very High
1-Star Price
ILS 67.53
5-Star Price
ILS 12.52
Economic Moat
Gmtrx
Capital Allocation
Is it the right time to buy, sell, or hold?
Start a free trial of Morningstar Investor to unlock exclusive ratings and continuous analyst coverage to help you decide if TEVA is a good fit for your portfolio.

News

Trading Information

Previous Close Price
Day Range
52-Week Range
Bid/Ask
/
Market Cap
Volume/Avg
/

Key Statistics

Price/Earnings (Normalized)
6.44
Price/Sales
1.19
Dividend Yield (Trailing)
Dividend Yield (Forward)
Total Yield

Company Profile

Teva Pharmaceutical Industries, based in Israel, is the leading generic drug manufacturer in the world. Teva derives half of its sales from North America and makes up a high-single-digit percentage of the total number of generic prescriptions in the US. It also has a significant presence in Europe, Japan, Russia, and Israel. Besides generics, Teva has a portfolio of innovative medicines and biosimilars in three main therapeutic areas: central nervous system with Copaxone, Ajovy, and Austedo; respiratory with Qvar and ProAir; and oncology with Truxima, Herzuma, and Bendeka/Treanda. Teva also sells active pharmaceutical ingredients, offers contract manufacturing services, and owns Anda, a US-based generic and specialty drug distributor.
Sector
Healthcare
Industry
Drug Manufacturers - Specialty & Generic
Stock Style Box
Large Value
Total Number of Employees
37,851

Competitors

Valuation

Metric
TEVA
VTRS
RDY
Price/Earnings (Normalized)
6.443.6317.86
Price/Book Value
2.560.613.52
Price/Sales
1.190.813.50
Price/Cash Flow
11.953.7415.42
Price/Earnings
TEVA
VTRS
RDY

Financial Strength

Metric
TEVA
VTRS
RDY
Quick Ratio
0.470.661.84
Current Ratio
0.891.672.58
Interest Coverage
0.181.1541.67
Quick Ratio
TEVA
VTRS
RDY

Profitability

Metric
TEVA
VTRS
RDY
Return on Assets (Normalized)
6.03%7.07%15.32%
Return on Equity (Normalized)
35.36%16.57%21.28%
Return on Invested Capital (Normalized)
12.54%9.85%19.75%
Return on Assets
TEVA
VTRS
RDY
See how this stock stacks up to its competitors with Morningstar Investor

Drug Manufacturers - Specialty & Generic Industry Comparables

1-Day Chart
Name
Price
Morningstar Rating for Stocks
Capital Allocation
Economic Moat
Market Cap
Merck KGaA ADR
MKKGY
GqfdskdfzCndxqp$77.8 Bil
Zoetis Inc Class A
ZTS
XlprydyygHjj$76.7 Bil
Haleon PLC ADR
HLN
JbdnpqzfQnvjf$38.2 Bil
Teva Pharmaceutical Industries Ltd ADR
TEVA
YlbmrrvxBkhh$19.4 Bil
Viatris Inc
VTRS
KbhchnrnMggdd$12.2 Bil
Dr Reddy's Laboratories Ltd ADR
RDY
GknctbwHjld$11.9 Bil
Catalent Inc
CTLT
BbdnfnzbGyczlb$9.9 Bil
Perrigo Co PLC
PRGO
LdqlfnrFlkg$3.5 Bil
Prestige Consumer Healthcare Inc
PBH
CzjrbtmyVbrtv$3.3 Bil
Curaleaf Holdings Inc
CURLF
GcsdfvjvCnnr$3.0 Bil

Sponsor Center